Heidelberg Pharma (HPHA) Q4 2024 earnings summary

Executive summary

• Achieved significant progress in clinical pipeline, with HDP-101 showing promising efficacy and safety in multiple myeloma, including a complete response and first objective responses in Phase I/II studies.

• Expanded proprietary ADC technology platforms, including Amanitin-based ATACs, Exatecan-based ADCs, and immunostimulatory ADCs, with a patent granted for Amanitin-based ADCs and collaboration with Binghamton University.

• Secured non-dilutive financing through amended royalty agreement with HealthCare Royalty and monetized part of Zircaix™ royalty stream, extending cash runway into 2027.

• Out-licensed legacy asset TLX250-CDx (Zircaix™) advanced to FDA priority review, with potential market launch in H2 2025.

• Expanded executive team with new CFO and CEO appointments in 2023 and early 2024.

Financial highlights

• FY 2024 sales revenue and other income totaled EUR 12 million, down from EUR 16.8 million in 2023, mainly due to lower partnership monetization.

• Net loss for FY 2024 was EUR 19.4 million, an improvement from EUR 20.3 million in 2023; basic loss per share improved to minus EUR 0.42.

• Cash position at year-end was EUR 29.4 million, down from EUR 43.4 million, reflecting business outflows and loan repayments.

• Financing cash flow improved to an inflow of EUR 22.8 million, driven by the HCRx transaction.

• Operating expenses for 2023 were EUR 38 million, up 3% year-over-year; R&D costs rose 6% to EUR 28.1 million.

Outlook and guidance

• FY 2025 sales revenue and other income expected between EUR 9 million and EUR 11 million.

• Operating expenses projected at EUR 40–45 million; EBIT expected between minus EUR 30 million and minus EUR 35 million.

• Cash inflow in 2025 anticipated at EUR 50–55 million, mainly from royalty agreement milestone payments.

• Company funded into 2027, even in case of delays in TLX250-CDx approval.

• Guidance to be updated as R&D plans evolve.